Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG revaccination in tuberculin-negative health students to evaluate surrogate markers of protection against mycobacterial infection
RBR-2gv984Completed
- Sponsor
- Fundação Oswaldo Cruz
- Start
- Jan 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of bcg vaccine in Tuberculosis (TB) (2 arms), sponsored by Fundação Oswaldo Cruz. Primary endpoint: Interferon-gamma response. Started Jan 2010; status: completed.
02
Drugs
bcg vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on RBR-2gv984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2gv984.